NCT04476017View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions
Parkinson DiseaseCognitive Dysfunction
Interventions
DRUG

SAGE-718

Oral tablets.

Trial Locations (4)

33407

Sage Investigational Site, West Palm Beach

33980

Sage Investigational Site, Port Charlotte

60612

Sage Investigational Site, Chicago

90806

Sage Investigational Site, Long Beach

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT04476017 - A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI) | Biotech Hunter | Biotech Hunter